NasdaqCM - Nasdaq Real Time Price USD

Sangamo Therapeutics, Inc. (SGMO)

Compare
0.6521
+0.0298
+(4.79%)
As of 1:36:39 PM EDT. Market Open.
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
57,800
57,800
176,232
111,299
110,701
Operating Expense
156,248
156,248
295,224
312,580
294,038
Operating Income
-98,448
-98,448
-118,992
-201,281
-183,337
Net Non Operating Interest Income Expense
5,861
5,861
11,102
9,432
5,346
Other Income Expense
-5,521
-5,521
-155,013
--
--
Pretax Income
-98,108
-98,108
-262,903
-191,849
-177,991
Tax Provision
-167
-167
-5,072
429
306
Net Income Common Stockholders
-97,941
-97,941
-257,831
-192,278
-178,286
Diluted NI Available to Com Stockholders
-97,941
-97,941
-257,831
-192,278
-178,286
Basic EPS
-0.49
-0.49
-1.48
-1.25
-1.23
Diluted EPS
-0.49
-0.49
-1.48
-1.25
-1.23
Basic Average Shares
201,699
201,699
174,444
154,345
144,568
Diluted Average Shares
201,699
201,699
174,444
154,345
144,568
Total Operating Income as Reported
-103,969
-103,969
-274,005
-201,281
-183,337
Total Expenses
156,248
156,248
295,224
312,580
294,038
Net Income from Continuing & Discontinued Operation
-97,941
-97,941
-257,831
-192,278
-178,286
Normalized Income
-92,429.3979
-92,429.3979
-105,808.5552
-192,278
-178,286
Interest Income
5,861
5,861
11,102
9,432
5,346
Net Interest Income
5,861
5,861
11,102
9,432
5,346
EBIT
-98,448
-98,448
-118,992
-201,281
-183,337
EBITDA
-89,087
-89,087
-96,800
-180,719
-165,699
Reconciled Depreciation
9,361
9,361
22,192
20,562
17,638
Net Income from Continuing Operation Net Minority Interest
-97,941
-97,941
-257,831
-192,278
-178,286
Total Unusual Items Excluding Goodwill
-5,521
-5,521
-155,013
--
--
Total Unusual Items
-5,521
-5,521
-155,013
--
--
Normalized EBITDA
-83,566
-83,566
58,213
-180,719
-165,699
Tax Rate for Calcs
0
0
0
0.0002
0.0003
Tax Effect of Unusual Items
-9.3979
-9.3979
-2,990.5552
--
--
12/31/2021 - 4/6/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.